Literature DB >> 2473021

Principles of radical surgery in gastric carcinoma.

J Fass1, V Schumpelick.   

Abstract

The principles of radical surgery for gastric carcinoma are discussed on the basis of 102 patients treated between 1985 and 1988. Early gastric carcinomas accounted for 11.8% of the cases. Tumor stage, localization and histopathological Lauren grading were the most important parameters influencing the decision on the extent of the excision. Thirteen (22.4%) of the 58 operations done with curative intent were subtotal gastrectomies for small antral tumors. The remaining 45 patients required total gastrectomy with splenectomy. A lymphadenectomy of compartment II was obligatory in all radical procedures. Despite high co-morbidity of the patients the postoperative mortality was 3.1% for total gastrectomy, 4.8% for subtotal gastrectomy and 6.3% for palliative bypass procedures.

Entities:  

Mesh:

Year:  1989        PMID: 2473021

Source DB:  PubMed          Journal:  Hepatogastroenterology        ISSN: 0172-6390


  4 in total

1.  Lymph node metastasis as a significant prognostic factor in early gastric cancer: analysis of 1,136 early gastric cancers.

Authors:  J P Kim; Y S Hur; H K Yang
Journal:  Ann Surg Oncol       Date:  1995-07       Impact factor: 5.344

2.  Total gastrectomy with simultaneous pancreaticosplenectomy or splenectomy in patients with advanced gastric carcinoma.

Authors:  E Otsuji; T Yamaguchi; K Sawai; K Okamoto; T Takahashi
Journal:  Br J Cancer       Date:  1999-04       Impact factor: 7.640

3.  Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Surgical Co-operative Group.

Authors:  A Cuschieri; S Weeden; J Fielding; J Bancewicz; J Craven; V Joypaul; M Sydes; P Fayers
Journal:  Br J Cancer       Date:  1999-03       Impact factor: 7.640

4.  Prospective comparison of D1 vs modified D2 gastrectomy for carcinoma.

Authors:  P Edwards; G R J C Blackshaw; W G Lewis; J D Barry; M C Allison; D R B Jones
Journal:  Br J Cancer       Date:  2004-05-17       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.